Preclinical evaluation of MET inhibitor INC-280 with or without the epidermal growth factor receptor inhibitor erlotinib in non–small-cell lung cancer

MS Lara, WS Holland, D Chinn, RA Burich… - Clinical lung cancer, 2017 - Elsevier
Background Although the epidermal growth factor receptor (EGFR) inhibitor erlotinib is
initially effective in non–small-cell lung cancer (NSCLC) patients with tumors harboring …
被引用次数：37 相关文章

Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non-Small-Cell Lung Cancer

MS Lara, WS Holland, D Chinn… - Clinical lung …, 2017 - pubmed.ncbi.nlm.nih.gov
Background Although the epidermal growth factor receptor (EGFR) inhibitor erlotinib is
initially effective in non-small-cell lung cancer (NSCLC) patients with tumors harboring …

[引用][C] Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non–Small-Cell Lung Cancer

MS Lara, WS Holland, D Chinn, RA Burich… - Clinical Lung …, 2017 - cir.nii.ac.jp
Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor
Receptor Inhibitor Erlotinib in Non–Small-Cell Lung Cancer | CiNii Research CiNii 国立情報学 …
[HTML] nih.gov

[HTML][HTML] Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non–Small-Cell Lung Cancer

MS Lara, WS Holland, D Chinn, RA Burich… - Clinical lung …, 2017 - ncbi.nlm.nih.gov
The MET inhibitor INC-280 restored sensitivity to erlotinib and promoted apoptosis in non–
small-cell lung cancer models rendered resistant to erlotinib by hepatocyte growth factor …

Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non-Small-Cell Lung Cancer.

MS Lara, WS Holland, D Chinn, RA Burich… - Clinical Lung …, 2016 - europepmc.org
Background Although the epidermal growth factor receptor (EGFR) inhibitor erlotinib is
initially effective in non-small-cell lung cancer (NSCLC) patients with tumors harboring …

Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non–Small-Cell Lung Cancer

MS Lara, WS Holland, D Chinn… - Clinical Lung …, 2017 - clinical-lung-cancer.com
Background Although the epidermal growth factor receptor (EGFR) inhibitor erlotinib is
initially effective in non–small-cell lung cancer (NSCLC) patients with tumors harboring …

Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non–Small-Cell Lung Cancer

MS Lara, WS Holland, D Chinn, RA Burich, PN Lara… - Clinical Lung …, 2017 - infona.pl
Although the epidermal growth factor receptor (EGFR) inhibitor erlotinib is initially effective in
non–small-cell lung cancer (NSCLC) patients with tumors harboring activating mutations of …

Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non–Small-Cell Lung Cancer

MS Lara, WS Holland, D Chinn, RA Burich… - Clinical Lung …, 2017 - escholarship.org
BackgroundAlthough the epidermal growth factor receptor (EGFR) inhibitor erlotinib is
initially effective in non-small-cell lung cancer (NSCLC) patients with tumors harboring …

Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non-Small-Cell Lung Cancer.

MS Lara, WS Holland, D Chinn, RA Burich… - Clinical Lung …, 2016 - europepmc.org
Background Although the epidermal growth factor receptor (EGFR) inhibitor erlotinib is
initially effective in non-small-cell lung cancer (NSCLC) patients with tumors harboring …